Genelux Corporation
HealthcareNASDAQ:GNLX · NASDAQ Global Market
+$0.08 today
Vol 0.11M · Avg 0.18M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-278.5%
avg -51.0%
ROIC
-251.1%
avg -65.7%
ROA
-168.9%
avg -161.5%
Analysis
ROA is currently the strongest return metric at -168.9% versus its period average of -161.5%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Thomas Zindrick | Chairman, Chief Executive Officer & President | $784,159.00 | — | 66 | $472,784.00 | 1.26% |
Matthew Pulisic | Chief Financial Officer and Principal Financial & Accounting Officer | $489,558.00 | — | 42 | $275,000.00 | 0.73% |
Joseph Cappello | Chief Technical Officer | $470,834.00 | — | 69 | $154,549.00 | 0.41% |
Yong Yu | Chief Scientific Officer | $242,615.00 | — | 54 | $149,706.00 | 0.40% |
Eric Groen | General Counsel, Corporate Secretary, Chief Compliance Officer & Head of Business Development | — | — | 55 | $0.00 | <0.01% |
Ralph Smalling | Vice President & Head of Regulatory Affairs | — | — | 71 | $67,611.00 | 0.18% |
Jason Litten | Chief Medical Officer | — | — | 52 | $275,000.00 | 0.73% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
24
$241,950.59
Net Sentiment
$241,950.59
Net selling
Most Active
Smalling Ralph
8 transactions
1–10 of 24
Analysis
Insiders reported 0 buys worth $0.00 and 24 sells worth $241,950.59 over the last 12 months. That adds up to net selling of $241,950.59. Smalling Ralph was the most active insider with 8 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | +190.4% (7yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Forward estimates point to Revenue at +190.4% (7yr), giving you a quick read on expected growth from here.
Competitors
Peer companies in the same sector
Alpha Tau Medical Ltd.
NASDAQ:DRTS
$889.71M
Candel Therapeutics, Inc.
NASDAQ:CADL
$469.95M
Contineum Therapeutics, Inc. Class A Common Stock
NASDAQ:CTNM
$444.15M
Lexeo Therapeutics, Inc. Common Stock
NASDAQ:LXEO
$343.14M
Silence Therapeutics plc
NASDAQ:SLN
$316.00M
Lyell Immunopharma, Inc.
NASDAQ:LYEL
$315.01M
Cellectis S.A.
NASDAQ:CLLS
$310.29M
AC Immune S.A.
NASDAQ:ACIU
$235.10M
Aldeyra Therapeutics, Inc.
NASDAQ:ALDX
$106.17M
Mereo BioPharma Group plc
MREO
$48.68M
Who manages GNLX?
Genelux Corporation (GNLX) lists 7 active executives. The top listed executive is Matthew Pulisic, Chief Financial Officer and Principal Financial & Accounting Officer.
Are GNLX insiders buying or selling?
Recent insider activity shows net selling of $1.64M.
Explore More
Continue the stock analysis
Jump to another research area for this company.